INSIGHTS ON UPSTREAM MANUFACTURING

• From DNA To IND In As Little As 6 Months

  Discover how an integrated, platform-driven CMC approach can accelerate your antibody program from DNA to IND in as little as six months while reducing risk and maintaining quality and regulatory alignment.

• ESACT 2026: Reducing Variability With Animal‑Origin‑Free Peptones

  Explore how data‑driven collaboration and animal‑origin‑free media strategies can reduce variability, improve cell culture performance, and support consistent, cost‑effective bioprocessing at scale.

• Providing Solutions In Titer, Host Cell Protein, And Scalability

  By leveraging expertise across a global network and executing a streamlined, rapid technology transfer, see how we were able to enable a highly data-driven approach to clone selection and process optimization.

• Scale Up Or Scale Out? Choosing An Adherent Cell Culture Platform

  Facility space costs up to $1,000/sq ft and planning timelines stretch 18 months, making your adherent cell culture platform choice one of the highest-stakes decisions in vaccine manufacturing scale-up.

• Aligning Upstream And Downstream Development (Part 1)

  4/20/2026

  In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.

• Where Sourcing Meets Science: Smarter Collaboration, Better Outcomes

  4/20/2026

  See how collaboration-driven raw material control reduces variability, improves cell culture performance, and delivers measurable cost and productivity gains in biotherapeutic manufacturing.

• What To Look For In A Cell Culture Media Supplier

  4/17/2026

  Choosing a cell culture media supplier is crucial in biopharmaceutical manufacturing. Explore five key factors to take into account when choosing a supplier and evaluating their capabilities.

• Automated T Cell Manufacturing From Start To Fill

  4/17/2026

  Gain insight into how an automated, closed workflow can integrate T cell enrichment, activation, transduction, expansion, and formulation across fresh and frozen starting materials.